Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc (NASDAQ: MRNA) is trading higher Wednesday after the company filed for authorization of its COVID-19 vaccine, a 50 microgram two-dose series of SPIKEVAX, with Health Canada to include children ages six to 11. Health Canada approved the New Drug Submission for SPIKEVAX for active immunization to prevent COVID-19 in individuals 12 years of age and older on Sept.

Why Moderna's Stock Is Moving Higher Today

Moderna's revised application, which was originally submitted in September, comes as the FDA is expected to authorize Pfizer and BioNTech's booster shots for all adults as early as this week.

Moderna submits FDA application to authorize Covid boosters for all adults

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Tops BioSpace's 2022 Best Places to Work Ranking in Large Employer Category

Moderna Tops BioSpace's 2022 Best Places to Work Ranking in Large Employer Category

Moderna Inc. MRNA, -0.34% said Wednesday it has applied for authorization of its COVID-19 vaccine in Canada for children aged 6 to 11. The vaccine is already allowed in Canada for individuals aged 12 years and older.

Moderna seeks EUA for its COVID-19 vaccine in Canada for children aged 6 to 11

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years

Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years

Penn Entertainment

These stocks have soared since the beginning of 2020, and they could more than double over the coming 12 months, according to high-water price targets.

3 High-Flying Growth Stocks With 104% to 123% Upside, According to Wall Street

Moderna, Inc.'s (NASDAQ:MRNA) vaccine franchise has further legs to play out, according to an analyst at Morgan Stanley. The Moderna Analyst: Matthew Harrison has an Equal-weight rating and a $313 price target for Moderna shares.

Can Moderna Deliver A Highly Effective Flu Vaccine?

AstraZeneca

AstraZeneca (AZN) and Moderna are developing an mRNA-based therapeutic to treat heart failure in patients undergoing coronary artery bypass surgery.

AstraZeneca (AZN), Moderna's Heart Failure Study Successful

Moderna Inc. MRNA, +1.68% said Tuesday the European Union and European Economic Area countries have agreed to donate more than 70 million doses of the company's COVID-19 vaccine to the Covax program in 2021, helping the World Health Organization-backed organization deliver vaccines to low-income countries. The initiative was led by France, Sweden and Norway and includes an initial donation of 15 million doses from France and 40 million from Germany.

Moderna says EU and EEA to donate more than 70 million COVID-19 vaccine does to Covax program in 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021

Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries

Where Will Moderna Be in 10 Years?

The NIH disagrees with Moderna over who deserves credit for inventing the company's COVID-19 vaccine.

Why Moderna Is Fighting Its Biggest Customer

Moderna Inc (NASDAQ: MRNA) announced data from the AstraZeneca Plc (NASDAQ: AZN)-led Phase 2 (EPICCURE) study evaluating AZD8601 in patients undergoing coronary artery bypass grafting (CABG). AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A).

AstraZeneca, Moderna Shares Early Cut Data For mRNA Candidate In Heart Failure

Moderna Inc. MRNA, -0.03% said Friday that a booster dose for its COVID-19 vaccine has been authorized by Health Canada for use in people at least 18 years old, at least six months after the completion of the primary two-dose regimen. Last month, U.S. regulators had signed off on extending boosters to Americans who got the Moderna or Johnson & Johnson JNJ, -0.46% vaccine, and said eligible people can get a brand different from the shots they originally received.

Moderna's COVID-19 vaccine boosters OK's by Health Canada

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Health Canada Authorizes Booster Dose of Moderna's COVID-19 Vaccine in Individuals 18 Years of Age and Older

Health Canada Authorizes Booster Dose of Moderna's COVID-19 Vaccine in Individuals 18 Years of Age and Older

These are Insider's biggest healthcare stories for November 15.

Why Moderna's betting big on gene editing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery

Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery

Moderna Inc (NASDAQ: MRNA) announced interim data from Phase 1 study of mRNA-2752 (Triplet) in patients with accessible solid tumors and lymphomas.  The data showed that the mRNA Triplet program given in combination with AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) was tolerated at all dose levels and elicited evidence of anti-tumor activity.

Moderna Posts Interim Data From mRNA Triplet Program In Solid Tumors

Noubar Afeyan launched 70 companies by pushing researchers to ask what if their craziest ideas were true. With $17 billion and a model of “parallel entrepreneurship,” he can fund a lot of wild notions.

The Billionaire Chairman Of Vaccine Maker Moderna Wants To Reinvent Scientific Entrepreneurship

The shares of Moderna Inc (NASDAQ: MRNA) have received a $404 price target from Barclays. These are the details.

Moderna (MRNA) Stock: $404 Price Target From Barclays

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting

Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting

Moderna won't win authorization for its COVID-19 vaccine in kids as soon as it hoped.

How Serious Are Moderna's FDA Delays?

Negative headlines have come in rapid fire for the company in recent weeks—and it dramatically missed sales estimates for the third quarter.

Moderna Stock Falls Back to Earth as Questions Mount

Moderna Inc (NASDAQ: MRNA) defended using its COVID-19 vaccine, saying the protection it offers outweighs the risk of myocarditis seen in a small number of young men who received the shot, reports CNBC. The FDA last week said it requires more time to decide whether to authorize Moderna's vaccine for use in children ages 12 to 17.

Moderna Says COVID-19 Vax Associated With Fewer Cases Than Pfizer's, But Higher Inflammatory Heart Conditions

Moderna defended the use of its Covid vaccine, saying the protection it offers against severe disease, hospitalization and death outweighs the risk of myocarditis.

News for Moderna Stock (MRNA)